Forum Markets, Incorporated · NASDAQ:FRMM
Forum Markets — 180 Life Sciences — SPAC Merger (October 2020)
33 slides from Forum Markets's SPAC merger presentation, Oct 13, 2020
Slide 1: Leading Research into Solving one of the World's Largest Drivers of Disease: Inflammation
Corporate Presentation Q4 2020 Leading Research into Solving one of the World’s Largest Drivers of Disease: Inflammation
Slide 2: Disclaimer and Forward-Looking Statements
180 Life Sciences Corp. www.180lifesciences.com Q4 2020 2 This Presentation is for informational purposes only and does not constitute an offer to sell, a solicitation of an offer to buy , or a recommendation to purchase any equity, debt or other financial instruments of 180 LIFE SCIENCES Corp. (“18
Slide 3: 180 Life Sciences Highlights
3 • Scientific team and founders are pioneers with proven track record in drug discovery from the University of Oxford, Hebrew University and Stanford University • Developing three families of novel drugs addressing significant market opportunities in inflammation, fibrosis and pain: ─ Fibrosis & An
Slide 4: Leadership
4 Leadership Prof Sir Marc Feldmann Co - Chairman • Pioneer of anti - TNF therapy, world’s biggest drug class ($40B USD pa) • Anti - TNF discovery eventually led to Centocor’s acquisition by J&J for $4.9 B USD • 7 International awards for Biomedical Innovation, including Crafoord and Lasker Awards ,
Slide 5: Three platform technologies and targeted diseases
5 FIBROSIS & ANTI - TNF (CLINICAL STAGE)* SYNTHETIC CBD ANALOGS (SCAs) a7nAChR TECHNOLOGIES Repurposing of anti - TNF for major unmet needs, other patented drugs Novel non - psychoactive synthetic CBD analogs Novel α7 nAChR agonists TARGETED DISEASES NEAR TERM • Early stage Dupuytren’s disease (DD)
Slide 6: Proposed Business Combination Overview
6 Proposed Business Combination Overview • KBL Merger Corp. IV (“ KBLM ”) has entered into a definitive business combination agreement with 180 Life Sciences Corp. (“ 180 Life Sciences ”) • The transaction is expected to close in early Q4 2020 • It is anticipated that the post - closing company will
Slide 7: KBL management team
7 Management team has worked together on investments and transactions for 20 years Name Experience Current and Past Affiliations Marlene Krauss, M.D. CEO and Director 30+ years of experience in acquiring, growing and selling more than 20 companies in healthcare services, pharmaceuticals and medica
Slide 8: KBL board of directors
8 Name Experience Current and Past Affiliations George Hornig Chairman 25+ years of senior operating, banking and investing experience CEO of RON Transatlantic Financial Holdings Former COO of Pine Bridge Investments, Credit Suisse Asset Management and Deutsche Bank (Americas) Co - founder a
Slide 9: Three Platform Technologies Targeting Multiple Indications
9 α7nAChR • Smoking cessation induced ulcerative colitis SCAs • Chronic pain • Early arthritis PLATFORM INDICATION PRECLINICAL PHASE 1 PHASE 2 PHASE 3 Fibrosis & Anti - TNF * • Dupuytren’s contracture • Frozen shoulder • PO C D • NASH Est. start Q1 2023 Est. start Q3 2022 started Q2 2020 Est. start
Slide 10: Clinical Stage Lead Program: Fibrosis & Anti-TNF
10 Clinical Stage Lead Program: Fibrosis & Anti - TNF Targeting common diseases - facilitates trials and potential sales Clinical trials supported by Prof Sallie Lamb, UK Developing targeted therapies for: • Early Stage Dupuytren’s disease (DD) - patent issued; Phase 2b/3 results expected Q4 2021 (1
Slide 11: Competitive Advantages
11 Competitive Advantages • Expert Investigators ─ Established reputation in conducting clinical trials across academic and clinical networks (1) ─ Well practiced in publishing trials in peer reviewed clinical journals • Cost Effective ─ No payment for trial patients required in the UK/EU ─ Staff co
Slide 12: TNF/TNFR2 signaling activates Wnt pathway and fibrosis
12 TNFR2 cell membrane extracellular intracellular Anti - TNF *Use - of patent issued for DD, patent pending for unique delivery system, current program TNF Anti - TNFR2 mab * patent pending, future program TNF Wnt activation leading to FIBROSIS (↑ expression of a - SMA, Col1A1 genes etc ) UNEXPECTE
Slide 13: Initial Indication Targeting Dupuytren's Disease
13 • Common localized fibrotic condition of the hand , develops over years • Nodules form under skin – eventually creating a thick cord pulling one or more fingers • Can limit hand functions • Unlike liver and lung fibrosis can be identified early Early disease Late disease – results in impaired han
Slide 14: Phase 2a Completed: Adalimumab is Effective
14 Phase 2a Completed: 40 mg (in 0.4ml) Adalimumab is Effective • Dose ranging with 28 patients. • 40 mg in 0.4ml - effective dose. • Funded by HICF ( Wellcome Trust + Dept of Health) and 180 Life Sciences Trial Overview Adalimumab injected directly into the nodule Demonstrated efficacy at high conc
Slide 15: Phase 2b/3 Trial Fully Enrolled
15 180 LIFE SCIENCES clinical trial 2b/3 - Nanchahal J et al, 2017 Wellcome Open Research, 2:37 Phase 2b/3 Trial Fully Enrolled – Local Adalimumab in Early DD • Randomized blinded trial in patients with early DD injected with optimal dose adalimumab (1) • Every 3 months for 1 year (4 injections), fo
Slide 16: Large Market Opportunity for Early Dupuytren's Disease
16 Large Market Opportunity for Early Dupuytren’s Disease Estimated future worldwide market for Dupuytren’s is a multi - billion dollar one (1) All current treatments for Dupuytren's are for LATE stage disease • 4% of the EU & US population suffer from Dupuytren’s disease (1,2) • Assume ~25% of thes
Slide 17: Additional Indications: POCD and Frozen Shoulder
17 Additional Indications • Over 300,000 hip fractures each year in the U.S. alone (1) • Strong clinical evidence for anti - TNF as preventative therapy • Patent claims granted, patent is licensed from Kennedy Trust, UK • Phase 2 multi - centre trial of pre - operative anti - TNF in hip fracture sur
Slide 18: Fibrosis & Anti-TNF Clinical Development Plan
18 Fibrosis & Anti - TNF Clinical Development Plan* Anti - TNF DD phase 2b/3 trial Ph 2b results P h 3 results Q4 2026 POCD results Q1 2024 Frozen Shoulder (FS) Preparation POCD Preparation Approval to do trial* Anti - TNF FS phase 2 trial Therapeutic development Ta rget identified Anti - TNF POCD p
Slide 19: Synthetic CBD Analogs (SCAs) for Pain and Inflammation
19 Synthetic CBD Analogs (SCAs) for Pain and Inflammation • Safe & non - psychoactive • Formulated to offer improved oral bioavailability (> three - fold) • Rigorously tested in clinical trials for inflammatory pain (efficacy and dosing) • Granted market approval by FDA, EMA and others • A real alte
Slide 20: SCA Pipeline
20 SCA Pipeline* Development of l ead SCA Phase 1 Phase 2a/b Chronic pain in RA R e s ul t s SCA pipeline Phase 2a/b in early arthritis (tbc) Therapeutic development of SCA 2 Preclinical development of SCA 2 Indication tbc 2020 2021 2022 2023 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 *Based on
Slide 21: a7nAChR Platform
21 a7nAChR Platform Led by Jonathan Rothbard and Larry Steinman Decade of research on immune suppression in multiple sclerosis led to realization of the importance of the a7 subunit of nicotinic Acetylcholine Receptor ( nAChR ) • a 7 nAChR also a central factor in evolutionarily ancient neural circu
Slide 22: a7 nAChR Platform, a Novel Therapeutic Platform for UC
22 Faster Time to Market Lower Development Costs Targeted Clinical Trial Novel Therapeutic Target Significant Unmet Need Repurposing drugs previously proven safe (targeted Alzheimer’s & Schizophrenia) Drugs stimulate vagal nerve, leading to localized anti - inflammatory response, similar to nicotine
Slide 23: a7nAChR Pipeline
23 Pre - clinical efficacy Lead identified Lead optimisation Clinical development For smoking cessation induced UC a7nAChr Pipeline* 2020 2021 2022 2023 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 *Based on current proposals. No regulatory approvals sought from appropriate authorities at this ti
Slide 24: 180 Life Sciences at a Glance
24 180 Life Sciences at a Glance *No meetings have been held with, and no applications or requests for approval have been submitted to the FDA for any product s a t this time. Scientific team and founders are pioneers with proven track record in drug discovery from the University of Oxford, Hebrew U
Slide 25: Thank you
www.180lifesciences.com 830 Menlo Avenue, Suite 100, Menlo Park, CA 94025 Thank you 25
Slide 26: Appendix
Appendix 26
Slide 27: Next Generation Therapeutics: Anti-TNFR2 & Anti-IL-33 Inhibitors
27 Next Generation Therapeutics: Anti - TNFR2 & Anti - IL - 33 Inhibitors Proposed mechanism: 1. Myofibroblasts secrete IL - 33 2. IL - 33 signals through ST2 receptor on mast cells and macrophages 3. Triggers production of TNF 4. TNF drives differentiation and activation of myofibroblasts Putative
Slide 28: Evidence That TNF Plays a Role in POCD
28 C Plasma TNF increases after surgery Surgery impaired fear memory is restored with pre - op anti - TNF Generated patent, licensed from Kennedy Inst. for treatment of POCD with anti - TNF Evidence That TNF Plays a Role in POCD In mice Forsberg A et al, Annals of Neurology (2017) 81:4, 572 - 582 Ka
Slide 29: SCA Platform Description
29 Platform Description OUR DRUGS 1. HU - 436 (1) 2. Domb patent 1 (2) 3. Mechoulam patent 2 (3) 4. Mechoulam patent 3 & others (3) HOW DOES IT WORK? OUR PRODUCTS: WHY MAN - MADE? • CBD signals through multiple GPCR receptors, e.g. CB2R, TRPV - 1, 5HT1α, GPR55, GPR18 and others • Anti - inflammatory
Slide 30: CBD - A Superior Treatment For Arthritis
30 CBD - A Superior Treatment For Arthritis Problem • Very early arthritis, pain & swelling is not effectively treated clinically • Nonsteroidals do not help, can increase TNF (1) • Existing therapies are suboptimal: ─ Methotrexate has side effects patients dislike ─ Anti - TNF is costly and use res
Slide 31: Fibrosis Program Patents
31 Fibrosis Program Patents METHOD OF TREATING EARLY STAGE DUPUYTREN'S DISEASE Country Application No. Date Filed Status Australia 2017248273 16/10/2018 Filed Canada 3020327 05/10/2018 Filed Europe 17779836 05/11/2018 Filed Hong Kong 19128046 12/08/2019 Filed U.S. 62/320,151 08/04/2016 Filed U.S. 16
Slide 32: Fibrosis Program Patents (cont'd)
32 Fibrosis Program Patents (cont’d) TREATMENT FOR DUPUYTREN’S DISEASE Country Application No. Date Filed/Granted Status Patent Number Note Australia 2011322482 06/07/2017 Granted 2,011,322,482 Australia 2017204267 05/09/2019 Granted 2,017,204,267 Canada 2,847,197 28/02/2014 Filed Europe 11779628.4
Slide 33: SCA & α7 nAChR Program Patents
33 SCA & α7 nAChR Program Patents SCA: CYCLOHEXENYL COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES Country Application No. Date Filed/Granted Status Note US2 10239848 26/03/2019 Granted Claims directed to a method for treating obesity or a disease/disorder associated therewith by administration of